FDA requires black-box warning on post-chemo anemia drugs

03/10/2007 | NYTimes.com · Washington Post, The

Makers of drugs used to treat patients with anemia that results from kidney failure or chemotherapy must add a black-box warning due to recent studies suggesting possible heart problems or death, the FDA says. The agency issued the new requirement for Amgen's Aranesp and Epogen and Johnson & Johnson's Procrit, both of in the Epo class of drugs.

View Full Article in:

NYTimes.com · Washington Post, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC